1/28
07:29 am
fold
Amicus Therapeutics (NASDAQ:FOLD) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.
Low
Report
Amicus Therapeutics (NASDAQ:FOLD) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.
1/23
07:37 am
fold
FOLD Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Amicus Therapeutics, Inc. is Fair to Shareholders
Low
Report
FOLD Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Amicus Therapeutics, Inc. is Fair to Shareholders
1/22
05:02 am
fold
Amicus Therapeutics (NASDAQ:FOLD) was downgraded by analysts at Jefferies Financial Group Inc. from a "buy" rating to a "hold" rating.
Low
Report
Amicus Therapeutics (NASDAQ:FOLD) was downgraded by analysts at Jefferies Financial Group Inc. from a "buy" rating to a "hold" rating.
1/9
07:03 pm
fold
Assessing Amicus Therapeutics (FOLD) Valuation After Recent Share Price Momentum [Yahoo! Finance]
Low
Report
Assessing Amicus Therapeutics (FOLD) Valuation After Recent Share Price Momentum [Yahoo! Finance]
1/9
04:31 am
fold
Is Amicus Therapeutics (FOLD) Pricing Reflect Recent 45% Surge And DCF Upside Potential [Yahoo! Finance]
Low
Report
Is Amicus Therapeutics (FOLD) Pricing Reflect Recent 45% Surge And DCF Upside Potential [Yahoo! Finance]
1/8
12:49 pm
fold
Halper Sadeh LLC Encourages THS, FOLD, REVG Shareholders to Contact the Firm to Discuss Their Rights
Low
Report
Halper Sadeh LLC Encourages THS, FOLD, REVG Shareholders to Contact the Firm to Discuss Their Rights
1/6
07:25 am
fold
Amicus Therapeutics (NASDAQ:FOLD) was downgraded by analysts at Guggenheim from a "strong-buy" rating to a "hold" rating.
Low
Report
Amicus Therapeutics (NASDAQ:FOLD) was downgraded by analysts at Guggenheim from a "strong-buy" rating to a "hold" rating.
12/29
08:00 am
fold
Amicus Therapeutics (NASDAQ:FOLD) was downgraded by analysts at Leerink Partners from an "outperform" rating to a "market perform" rating. They now have a $14.50 price target on the stock.
Low
Report
Amicus Therapeutics (NASDAQ:FOLD) was downgraded by analysts at Leerink Partners from an "outperform" rating to a "market perform" rating. They now have a $14.50 price target on the stock.
11/4/2025
07:00 am
fold
amicus therapeutics, inc.
BEAT
Report
-1.2%
amicus therapeutics, inc.
7/31/2025
07:00 am
fold
amicus therapeutics, inc.
BEAT
Report
-6.4%
amicus therapeutics, inc.
5/1/2025
07:00 am
fold
amicus therapeutics, inc.
BEAT
Report
-9.7%
amicus therapeutics, inc.
2/19/2025
07:00 am
fold
amicus therapeutics, inc.
BEAT
Report
-4.3%
amicus therapeutics, inc.
1/26
08:12 am
fold
Form DEFA14A AMICUS THERAPEUTICS,
Low
Report
Form DEFA14A AMICUS THERAPEUTICS,
1/26
08:11 am
fold
Form 8-K AMICUS THERAPEUTICS, For: Jan 26
Low
Report
Form 8-K AMICUS THERAPEUTICS, For: Jan 26
1/22
07:27 pm
fold
Form 4 AMICUS THERAPEUTICS, For: Jan 20 Filed by: Campbell Bradley L
Low
Report
Form 4 AMICUS THERAPEUTICS, For: Jan 20 Filed by: Campbell Bradley L
1/21
04:18 pm
fold
Form PREM14A AMICUS THERAPEUTICS, For: Jan 21
Low
Report
Form PREM14A AMICUS THERAPEUTICS, For: Jan 21
1/20
04:27 pm
fold
Form 144 AMICUS THERAPEUTICS, Filed by: Campbell Bradley L
Low
Report
Form 144 AMICUS THERAPEUTICS, Filed by: Campbell Bradley L
1/6
07:48 pm
fold
Form 4 AMICUS THERAPEUTICS, For: Jan 02 Filed by: Rosenberg Ellen
Low
Report
Form 4 AMICUS THERAPEUTICS, For: Jan 02 Filed by: Rosenberg Ellen
1/6
07:47 pm
fold
Form 4 AMICUS THERAPEUTICS, For: Jan 02 Filed by: Castelli Jeff
Low
Report
Form 4 AMICUS THERAPEUTICS, For: Jan 02 Filed by: Castelli Jeff
1/6
07:46 pm
fold
Form 4 AMICUS THERAPEUTICS, For: Jan 02 Filed by: Prout Samantha
Low
Report
Form 4 AMICUS THERAPEUTICS, For: Jan 02 Filed by: Prout Samantha
News Stats
All News
News Wires
Media Monitoring
SEC Edgar Filings
Upgrades
Downgrades
Initiated
Reiterated
Last Earnings
Last Earnings EPS
Next Earnings
Order Stats
Sub-Penny
Odd lot
Avg. bid-ask spread
Avg. bid-ask size
Shares at ask/bid
Off exchange
Main News & Impact Reports
4/2
Amicus Therapeutics, Inc. (NASDAQ: FOLD) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating.
8.5%
2/4
Amicus Therapeutics, Inc. (NASDAQ: FOLD) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $20.00 price target on the stock, up previously from $19.00.
7.0%
3/9
Form 4 AMICUS THERAPEUTICS, For: Mar 05 Filed by: Campbell Bradley L
6.9%
2/4
Form 4 AMICUS THERAPEUTICS, For: Jan 31 Filed by: Crowley John F
6.5%
6/17
Amicus Therapeutics, Inc. (NASDAQ: FOLD) is now covered by analysts at HC Wainwright. They set a "buy" rating on the stock.
5.8%
1/14
Form 4 AMICUS THERAPEUTICS, For: Jan 10 Filed by: Barth Jay
5.4%
10/3
Is Amicus Therapeutics, Inc. (NASDAQ:FOLD) A Volatile Stock? [Yahoo! Finance News]
4.8%
3/24
Form 4 AMICUS THERAPEUTICS, For: Mar 20 Filed by: Crowley John F
4.4%
7/17
Amicus Therapeutics, Inc. (NASDAQ: FOLD) was given a new $18.00 price target on by analysts at HC Wainwright. They now have a "buy" rating on the stock.
4.4%
4/24
Amicus Therapeutics to Announce First Quarter 2020 Financial Results on May 7, 2020
4.3%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below:
Register